We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

146 hedge funds and large institutions have $1.13B invested in Karyopharm Therapeutics in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

373% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 11

101% more capital invested

Capital invested by funds: $563M → $1.13B (+$567M)

38% more funds holding

Funds holding: 106 → 146 (+40)

5% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $15.6M

5% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 39

0.04% less ownership

Funds ownership: 6.3% → 6.26% (-0.04%)

Holders
146
Holders Change
+40
Holders Change %
+37.74%
% of All Funds
2.88%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.1%
New
52
Increased
41
Reduced
39
Closed
11
Calls
$16.5M
Puts
$15.6M
Net Calls
+$838K
Net Calls Change
+$955K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$30.2M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$14.2M
3
Federated Hermes
Federated Hermes
Pennsylvania
+$11.8M
4
Two Sigma Investments
Two Sigma Investments
New York
+$10.6M
5
ACP
Acuta Capital Partners
California
+$5.1M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$63.6M
2
Millennium Management
Millennium Management
New York
-$18.4M
3
EA
Emerald Advisers
Pennsylvania
-$14.4M
4
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$13.7M
5
ECP
Elk Creek Partners
Colorado
-$11.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
101
Legal & General Group
United Kingdom
$306K +$39.7K +183 +21%
UBS Group
102
UBS Group
Switzerland
$294K -$2.73M -12,561 -92%
WMSA
103
Weiss Multi-Strategy Advisers
New York
$288K -$145K -667 -40%
BRWA
104
B. Riley Wealth Advisors
Florida
$288K +$217K +1,000 New
Jane Street
105
Jane Street
New York
$286K -$93.7K -432 -30%
Millennium Management
106
Millennium Management
New York
$259K -$18.4M -84,813 -99%
Mackenzie Financial
107
Mackenzie Financial
Ontario, Canada
$251K +$189K +872 New
Baird Financial Group
108
Baird Financial Group
Wisconsin
$249K +$188K +867 New
GAM
109
Gotham Asset Management
New York
$237K +$179K +825 New
Los Angeles Capital Management
110
Los Angeles Capital Management
California
$233K +$176K +809 New
OAM
111
Oxford Asset Management
United Kingdom
$230K -$171K -788 -50%
AQR Capital Management
112
AQR Capital Management
Connecticut
$222K +$168K +773 New
QT
113
Quantbot Technologies
New York
$216K +$163K +753 New
AB
114
Amalgamated Bank
New York
$208K +$8.89K +41 +6%
AG
115
Aperio Group
California
$207K +$156K +720 New
SIM
116
Spark Investment Management
New York
$207K +$156K +720 New
SPC
117
Sigma Planning Corp
Michigan
$203K +$153K +707 New
Commonwealth Equity Services
118
Commonwealth Equity Services
Massachusetts
$192K -$41.7K -192 -22%
SG Americas Securities
119
SG Americas Securities
New York
$167K +$126K +581 New
Bank of Montreal
120
Bank of Montreal
Ontario, Canada
$145K +$34.7K +160 +47%
BNP Paribas Financial Markets
121
BNP Paribas Financial Markets
France
$133K -$17.6K -81 -15%
AIP
122
Ameritas Investment Partners
Nebraska
$94K – – –
TRCT
123
Tower Research Capital (TRC)
New York
$89K +$16.9K +78 +34%
Zurich Cantonal Bank
124
Zurich Cantonal Bank
Switzerland
$75K – – –
PNC Financial Services Group
125
PNC Financial Services Group
Pennsylvania
$73K – – –
3 4
5
6 7

KPTI Hedge Fund Activity: Q4 2019 in Review

146 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2019, worth a combined $1.13B — up 101% from $563M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new KPTI positions and 11 closed out — a net gain of 41 holders — while 41 added to existing stakes and 39 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $30.2M. The largest seller was Wellington Management Group, cutting an estimated $63.6M.

  • 146 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2019, up from 106 in Q3 2019.
  • Funds reported $1.13B of Karyopharm Therapeutics stock for Q4 2019, up 101% quarter-over-quarter.
  • 52 funds opened new Karyopharm Therapeutics positions in Q4 2019 and 11 closed out, a net change of +41 holders.
  • The largest Karyopharm Therapeutics buyer in Q4 2019 was Adage Capital Partners, an estimated $30.2M added.
  • The largest Karyopharm Therapeutics seller in Q4 2019 was Wellington Management Group, an estimated $63.6M sold.

Based on aggregated 13F filings for Q4 2019.